CliffBio
small molecule

PREVYMIS

LETERMOVIR

Loss of exclusivityFebruary 2033latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME CORP

Drug detail

Brand namePREVYMIS
Active ingredientLETERMOVIR
Strength240MG/12ML (20MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2017
Marketing statusRX

Listed patents

PatentExpiresType
10603384February 2033product
RE46791January 2029substance, product

Regulatory exclusivity

CodeExpires
ODE-495August 2031
ODE-497August 2031
ODE-423June 2030
NPPAugust 2027
D-189August 2026
I-916June 2026

More from MERCK SHARP AND DOHME CORP

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PREVYMIS patent cliff — loss of exclusivity February 2033 | CliffBio